New implant combo aims to lower eye pressure without daily drops

NCT ID NCT06066645

Recruiting now Disease control Sponsor: Glaukos Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a travoprost drug implant (iDose TR) plus a tiny stent (iStent infinite) can lower eye pressure better than the implant alone in people with open-angle glaucoma or high eye pressure. About 150 adults will receive either the combo or a sham procedure and be followed for 12 months. The goal is to see if the combo provides a longer-lasting pressure drop.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Travoprost intraocular implant (iDose TR) plus iStent infinite device
What this could lead to: If successful, this combination could offer a more effective, long-lasting way to lower eye pressure and reduce the need for daily eye drops in glaucoma patients.
What could go wrong: This is a Phase 4 trial with only 150 participants, so results may not apply to everyone. Risks include eye irritation, infection, or the implant not working as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA, OPEN-ANGLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA, OPEN-ANGLE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Glaukos Clinical Study Site
RECRUITING

Oklahoma City, Oklahoma, 73112, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.